Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ACAD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Pimavanserin Tartrate FDA approved Apr 2016 · Nuplazid |
Parkinson's Disease Psychosis | Phase 3 · NCT01174004 | Completed |
| Trofinetide FDA approved Mar 2023 · Daybue |
Rett Syndrome | Phase 3 · NCT04776746 | Terminated |
| ACP-204 | Lewy Body Dementia Psychosis | Phase 3 · NCT07095465 | Recruiting |
| Carbetocin | Hyperphagia in Prader-Willi Syndrome | Phase 3 · NCT06173531 | Completed |
| ACP-044 Dose A | Osteoarthritis Pain | Phase 2 · NCT05008835 | Terminated |
| ACP-044 Dose B | Osteoarthritis Pain | Phase 2 · NCT05008835 | Terminated |
| ACP-104 | Schizophrenia | Phase 2 · NCT00490516 | Completed |
| ACP-211 | Major Depressive Disorder (MDD) | Phase 2 · NCT07284667 | Recruiting |
| Active drug: pimavanserin 17mg (2 strength… | Parkinson Disease | Phase 2 · NCT03947216 | Completed |
| Pimavanserin 34 milligrams (MG) [Nuplazid] | Schizophrenia | Phase 2 · NCT03994965 | Withdrawn |
Also used in these trials (approved or third-party drugs, not ACAD's own candidates): Pimavanserin, Quetiapine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ACAD holds $976.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACAD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Julian C. Baker | Institution (13G, 5%+) | 43,294,373 | 25.05% | 2026-02-24 |
| BAKER BROS. ADVISORS LP Director, 10% owner · +32,008 options |
Insider | 39,487,463 | 22.85% | 2026-05-29 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 8,781,007 | 5.08% | 2026-03-31 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER · +157,929 options |
Insider | 71,322 | 0.04% | 2026-10-15 |
| Daniel B Soland Director · +21,900 options |
Insider | 44,041 | 0.03% | 2025-05-29 |
| Edmund Harrigan Director · +39,108 options |
Insider | 43,148 | 0.02% | 2026-05-29 |
| Elizabeth A. Garofalo Director · +39,108 options |
Insider | 33,489 | 0.02% | 2026-05-29 |
| Adora Ndu Director · +39,108 options |
Insider | 32,908 | 0.02% | 2026-05-29 |
| Laura Brege Director · +25,315 options |
Insider | 23,202 | 0.01% | 2026-05-29 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev · +133,846 options |
Insider | 18,994 | 0.01% | 2026-07-29 |
| Adams Catherine Owen Chief Executive Officer, Director · +333,535 options |
Insider | 14,803 | 0.01% | 2026-03-24 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER · +24,362 options |
Insider | 13,088 | 0.01% | 2026-06-26 |
Share count 172,828,972 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACAD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →